New — Free Peptide Starter Guide (2026): 13 chapters, 34 cited studies

Get it free
ToolsCompareVesugen vs HGH Fragment 176-191

Vesugen vs HGH Fragment 176-191

Side-by-side comparison of key properties, dosing, and research.

Anti-Aging & Longevity
Vesugen
Fat Loss & Metabolic
HGH Fragment 176-191
Summary
Vesugen is a tripeptide bioregulator (Lys-Glu-Asp) developed by Professor Vladimir Khavinson, tissue-specific for blood vessels and the vascular endothelium. It supports endothelial cell function, promotes vascular wall integrity, and is studied for atherosclerosis prevention, vascular aging, and cardiovascular health maintenance. It is one of the more broadly applicable Khavinson bioregulators given the ubiquity of vascular tissue.
HGH Fragment 176-191 (also known as AOD-9604) is a stabilized, modified fragment of the human growth hormone molecule corresponding to amino acids 176–191 with an addition of a tyrosine residue at the N-terminus. It retains HGH's fat-burning properties without the anabolic, diabetogenic, or IGF-1-stimulating effects.
Half-Life
Short (minutes); sustained gene-regulatory effects
~30 minutes
Admin Route
SubQ, Oral
SubQ
Research
Typical Dose
10 mg per day
250–500 mcg
Frequency
Daily for 10–30 days
1–3 times daily
Key Benefits
  • Supports vascular endothelial cell function and integrity
  • May reduce endothelial inflammation and dysfunction
  • Anti-aging effects on blood vessel walls
  • Potential benefits in early atherosclerosis and vascular aging
  • Supports nitric oxide-mediated vascular tone
  • Reduces endothelial apoptosis from oxidative stress
  • Complementary to Cardiogen and Epithalon in cardiovascular longevity protocols
  • Selective fat burning without anabolic side effects
  • Reduces visceral and subcutaneous fat
  • No insulin resistance or blood glucose disruption
  • Does not stimulate IGF-1
  • May support cartilage and bone repair (at higher doses)
  • No effect on growth or organ size
Side Effects
  • Generally well tolerated
  • Mild injection site reactions
  • No significant vascular adverse events reported at standard doses
  • Injection site irritation
  • Temporary lethargy
  • Headache (rare)
  • Nausea (rare)
Stacks With